Eagle Bay Advisors’s AstraZeneca AZN Stock Holding History

Eagle Bay Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-164	Closed	-$30.2K	–	141
2025 Q4	$30.2K	Buy	+164	New	+$28.8K	0.02%	205
2025 Q1	–	Sell	-124	Closed	-$16.2K	–	192
2024 Q4	$16.2K	Sell	124 -507	-80%	-$71K	0.01%	490
2024 Q3	$176K	Buy	631 +506	+405%	+$81.7K	0.07%	188
2024 Q2	$19.4K	Buy	125 +37	+42%	+$5.57K	0.01%	444
2024 Q1	$11.9K	Buy	+88	New	+$11.7K	0.01%	540
2023 Q2	–	Sell	-7	Closed	-$902	–	847
2023 Q1	$902	Hold	7	–	–	﹤0.01%	826
2022 Q4	$881	Hold	7	–	–	﹤0.01%	837
2022 Q3	$1K	Hold	7	–	–	﹤0.01%	802
2022 Q2	$859	Buy	+7	New	+$918	﹤0.01%	933
2022 Q1	–	Sell	-13	Closed	-$2K	–	347
2021 Q4	$2K	Sell	13 -138	-91%	-$16.2K	﹤0.01%	891
2021 Q3	$19K	Buy	+151	New	+$17.6K	0.01%	619

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Eagle Bay Advisors's AZN Position: Q1 2026 in Review

Eagle Bay Advisors sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 164 shares — an estimated $30.2K sold.

Eagle Bay Advisors first reported a position in AZN in Q3 2021 and held it in 11 quarters. The position peaked at $176K in Q3 2024. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Eagle Bay Advisors reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Eagle Bay Advisors sold 164 AstraZeneca shares in Q1 2026, an estimated $30.2K.
Eagle Bay Advisors first reported a position in AstraZeneca in Q3 2021 and held it in 11 quarters.
Eagle Bay Advisors's AstraZeneca position peaked at $176K in Q3 2024.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Eagle Bay Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.